Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.
Hanna Bergman, Nicholas Henschke, Ingrid Arevalo-Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/41276263/Actively Recruiting
Led by London School of Hygiene and Tropical Medicine · Updated on 2026-09-08
10400
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the impact of adding a single-dose male HPV vaccination to the existing national HPV vaccination program for girls in northern Tanzania. This phase 4 cluster-randomized trial compares communities offering only the national program for girls aged about 14 years with those that also provide a single dose of the 4-valent HPV vaccine Gardasil to boys aged 14 to 18 years. The goal is to assess population genital HPV prevalence three years after vaccination in both males and females aged 18 to 21 years. In the intervention communities, boys aged 14 to 18 years receive one dose of Gardasil, which protects against HPV types 6, 11, 16, and 18. Girls aged 14 years in all communities receive two doses of Gardasil through the national vaccination program. Blood samples for immune response and safety monitoring are collected from a subset of 200 male participants in selected intervention clusters. The study is randomized with two parallel arms conducted across 26 communities. Participants are monitored for HPV prevalence at 36 months post-vaccination. The study also evaluates immunogenicity and safety at 12, 24, and 36 months, vaccine uptake and coverage, acceptability of a gender-neutral vaccination approach, and cost-effectiveness outcomes. Safety data and immune responses are collected through blood sampling in a subset of boys. The total study duration extends from August 2022 through December 2026.
CONDITIONS
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
D
Deborah Watson-Jones, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
London School of Hygiene and Tropical Medicine
Lead Sponsor
Mwanza Intervention Trials Unit, National Institute for Medical Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 36 months
Participants receive either the national HPV vaccination program for girls only or this program plus a single-dose HPV vaccine for boys in intervention communities. Selected boys will have blood samples taken to monitor immune response and safety.
Multiple visits for vaccination and blood sampling
Duration - At 36 months post-vaccination
Researchers assess HPV infection prevalence in males and females aged 18 to 21 years to evaluate the impact of the vaccination program.
1 visit for HPV prevalence assessment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hanna Bergman, Nicholas Henschke, Ingrid Arevalo-Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/41276263/London School of Hygiene and Tropical Medicine
Lead Sponsor
Mwanza Intervention Trials Unit, National Institute for Medical Research
Collaborating Sponsor